Hyperprolactinemia and estimated dopamine D2 receptor occupancy in patients with schizophrenia: Analysis of the CATIE data  by Tsuboi, Takashi et al.
Progress in Neuro-Psychopharmacology & Biological Psychiatry 45 (2013) 178–182
Contents lists available at SciVerse ScienceDirect
Progress in Neuro-Psychopharmacology & Biological
Psychiatry
j ourna l homepage: www.e lsev ie r .com/ locate /pnpHyperprolactinemia and estimated dopamine D2 receptor occupancy
in patients with schizophrenia: Analysis of the CATIE dataTakashi Tsuboi a, Robert R. Bies b,c,d, Takefumi Suzuki a,f, David C. Mamo e,g,h, Bruce G. Pollock b,e,
Ariel Graff-Guerrero e,g, Masaru Mimura a, Hiroyuki Uchida a,b,⁎
a Department of Neuropsychiatry, Keio University School of Medicine, Tokyo, Japan
b Geriatric Mental Health Program, Centre for Addiction and Mental Health, Toronto, ON, Canada
c Division of Clinical Pharmacology, Indiana University School of Medicine, Indianapolis, IN, USA
d Indiana Clinical and Translational Sciences Institute, Indianapolis, IN, USA
e Department of Psychiatry, University of Toronto, Toronto, ON, Canada
f Department of Psychiatry, Inokashira Hospital, Tokyo, Japan
g Multimodal Imaging Group, Centre for Addiction and Mental Health, Toronto, ON, Canada
h Department of Psychiatry, University of Malta, Valletta, MaltaAbbreviations: CATIE, Clinical Antipsychotic Trials
PET, positron emission tomography.
⁎ Corresponding author at: Department of Neuropsych
Medicine, 35 Shinanomachi, Shinjuku-ku, Tokyo 160-8
3829; fax: +81 3 5379 0187.
E-mail address: mcn41320@biglobe.ne.jp (H. Uchida
0278-5846 © 2013 The Authors. Published by Elsevier I
http://dx.doi.org/10.1016/j.pnpbp.2013.05.010a b s t r a c ta r t i c l e i n f oArticle history:
Received 13 March 2013
Received in revised form 18 May 2013
Accepted 22 May 2013
Available online 29 May 2013
Keywords:
CATIE
Dopamine D2 receptor occupancy
Hyperprolactinemia
Schizophrenia
Background: Large-scale data are still lacking on the relationship between serum prolactin concentration and
dopamine D2 receptor occupancy in patients with schizophrenia treated with antipsychotics.
Methods: The dataset from 481 subjects (risperidone, N = 172, olanzapine, N = 211, and ziprasidone, N = 98)
who participated in Phase 1 of the Clinical Antipsychotic Trials in Intervention Effectiveness (CATIE) was used in
the present analysis. Dopamine D2 receptor occupancy levels on the day of the measurement of serum prolactin
level were estimated from plasma antipsychotic concentrations. A multivariate general linear model was used to
examine effects of clinical and demographic characteristics, including estimated D2 occupancy levels, on serum
prolactin concentrations. Individual subjects were divided into two groups, stratiﬁed by the presence of
hyperprolactinemia. To evaluate the performance of this binary classiﬁcation, sensitivity, speciﬁcity, and accuracy
of consecutive cut-off points in the D2 occupancy were calculated.
Results: The multivariate general linear model revealed that estimated D2 occupancy levels had signiﬁcant effects
on serum prolactin concentrations while any other variables failed to show signiﬁcant effects. The cut-off point
associated with 0.5 or greater, in both sensitivity and speciﬁcity with the greatest accuracy, was 73% (sensitivity,
0.58; speciﬁcity, 0.68; accuracy = 0.64) (68–70% for risperidone, 77% for olanzapine, and 55% for ziprasidone.).
Conclusion: The threshold for hyperprolactinemia in D2 occupancy may lie somewhat on a lower side of the
established therapeutic window with antipsychotics (i.e. 65–80%). This ﬁnding highlights the need for the use
of the lowest possible dose to avoid this hormonal side effect in the treatment of schizophrenia.© 2013 The Authors. Published by Elsevier Inc. Open access under CC BY-NC-ND license. 1. Introduction
Hyperprolactinemia is a common side effect induced by antipsy-
chotic agents in the treatment of schizophrenia (Bostwick et al., 2009;
Hummer and Huber, 2004) and can result in a number of physicalin Intervention Effectiveness;
iatry, Keio University School of
582, Japan. Tel.: +81 3 5363
).
nc. Open access under CC BY-NC-ND licenseconsequences including amenorrhea, galactorrhea, infertility, erectile
dysfunction, ejaculation deﬁciency, and loss of libido (Bostwick et al.,
2009; Byerly et al., 2007; Hamner, 2002; Hummer and Huber, 2004;
Rettenbacher et al., 2010). Moreover, the long-term elevation of serum
prolactin has been associated with decreased bone mineral density and
increased risk of breast cancer in post-menopausal women (Kishimoto
et al., 2008; Meaney et al., 2004; Wang et al., 2000). The adverse effects
of antipsychotics represent an obstacle to adherence to treatment in
patients with schizophrenia (Lieberman et al., 2005). Given that the
non-adherence is the major cause of relapse and exacerbation (Kane,
2007), every effort should be made to minimize these annoying side
effects as much as possible.
Antipsychotic-induced hyperprolactinemia is a result of disinhibition
of the lactotroph cells in the anterior pituitary gland (which lie outside
the blood–brain barrier) through dopamine D2 receptor antagonism. 
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receptor occupancy in the pituitarywas a predictor of hyperprolactinemia
(Arakawa et al., 2010). In this study, 11 healthy men receiving sulpiride
and 24 male patients with schizophrenia receiving one of the four differ-
ent antipsychotics (i.e. risperidone, olanzapine, haloperidol, or sulpiride)
underwent positron emission tomography (PET) scanning. Signiﬁcant
positive correlationwas observed between serumprolactin concentration
and dopamine D2 receptor occupancy in the pituitary (r = 0.62, p =
0.001). On the other hand, a positive association between dopamine D2
occupancy levels and serum prolactin level has not always been a consis-
tent ﬁnding in the literature (Kapur et al., 2000; Mamo et al., 2004;
Remington et al., 2006), though this may be attributable to small sample
sizes as well as different D2 receptor binding afﬁnity and penetration of
the blood brain barrier of the antipsychotic drugs used in the smaller
PET studies.
Antipsychotic-induced hyperprolactinemia is widely considered
inevitable, particularly when using ﬁrst generation antipsychotics
and high potency second generation antipsychotics. This assumption
has not been formally tested empirically, and creates a certain thera-
peutic indifference in the clinical management of hyperprolactinemia
in schizophrenia, a position that is no longer tenable given the
growing body of literature concerning long-term adverse effects of
prolactin elevation.
We have developed a model with which the dopamine D2 receptor
occupancy by antipsychotic drugs, including risperidone, olanzapine,
and ziprasidone, can be reliably estimated from plasma concentrations
of these drugs (Uchida et al., 2011b). In addition, recent advances in
nonlinear, mixed-effects population pharmacokinetic methods have
made it possible to estimate individual pharmacokinetic parameters for
antipsychotic drugs, including peak and trough plasma concentrations,
using two or more sparsely collected blood samples (Bigos et al., 2006).
By combining these models, the dopamine D2 receptor occupancy levels
at any given point in time can be reliably estimated, using the measure-
ment of antipsychotic plasma concentrations at two separate random
time points (Uchida et al., 2009a).
For the purpose of providing robust ﬁndings on the relationship
between dopamine D2 receptor blockade and serum prolactin con-
centration in a large sample, the Clinical Antipsychotic Trials in Inter-
vention Effectiveness (CATIE) (Stroup et al., 2003) provides an ideal
dataset in light of its unprecedented large sample size and availability
of plasma antipsychotic concentrations for which population phar-
macokinetic models have already been developed with respect to
risperidone, olanzapine, and ziprasidone (Bigos et al., 2008; Feng et al.,
2008; Wessels et al., 2011). The objective of this report was to evaluate
the relationship between estimated dopamine D2 receptor occupancy
with risperidone, olanzapine, and ziprasidone and hyperprolactinemia
in patients with schizophrenia in the CATIE.
2. Methods
2.1. Study design
The CATIE was funded by the National Institute of Mental Health
to compare the effectiveness of second-generation antipsychotics
and a ﬁrst-generation antipsychotic medication in patients with
schizophrenia; the details of the study were reported elsewhere
(Stroup et al., 2003). Brieﬂy, the study was performed between
January 2001 and December 2004 at 57 clinical sites in the United
States. One thousand four hundred and ninety-three patients between
ages 18 and65with adiagnosis of schizophrenia on thebasis of the Struc-
tured Clinical Interview of the DSM-IV participated in the CATIE. Patients
were initially randomized to risperidone (1.5–6.0 mg/day), olanzapine
(7.5–30 mg/day), ziprasidone (40–160 mg/day), quetiapine (200–
800 mg/day), or perphenazine (8–32 mg/day) under double-blind
conditions and received treatments for up to 18 months or until
treatment was discontinued for any reason (Phase 1).Data used in the present analysis were derived from subjects who
were receiving risperidone, olanzapine, or ziprasidone, had serum
prolactin concentration measured at 3 months in Phase 1a, and pro-
vided plasma samples for the assessment of antipsychotic concentra-
tions. Subjects randomized to these three drugs were included in the
present study since the prediction models of dopamine D2 receptor
occupancy from plasma drug concentrations were available for
those three drugs (Bigos et al., 2008; Feng et al., 2008; Wessels et
al., 2011). All participants gave written informed consent to partici-
pate in the protocols approved by the local institutional review
boards.
2.2. Population pharmacokinetic analysis
Subjects who participated in the CATIE provided plasma
samples for the measurement of concentrations of risperidone plus
9-hydroxyrisperidone (active moiety), olanzapine, or ziprasidone at
more than one time point. Using these samples, plasma antipsychotic
concentrations at peak and trough that corresponded to the dose
given at 3 months were calculated for each individual, using the
established population pharmacokinetic models and extracting the
Empirical Bayes Estimates for the pharmacokinetic parameters from
each of these individuals (Sheiner et al., 1977; Beal and Sheiner,
1992). The precision and reliability of this estimation has recently
been conﬁrmed in our population pharmacokinetic study (Uchida
et al., 2012). The nonlinear mixed-effect models for risperidone,
olanzapine, and ziprasidone were previously established using the
CATIE data (Bigos et al., 2008; Feng et al., 2008; Wessels et al., 2011).
These original studies used to establish the population pharmacokinetic
models comprised 1236 risperidone plus 9-hydroxyrisperidone concen-
trations from 490 subjects, 1527 olanzapine concentrations from 523
subjects, and 568 ziprasidone concentrations from 233 subjects,
respectively. All three compounds were adequately described by using
a one-compartment linear model with ﬁrst order absorption. The
previously established models utilized exponentiated or log-normal
interindividual variability on each pharmacokinetic parameter, a mix-
ture distribution to assign the tri-modal distribution of risperidone of
clearance as CYP 2D6 genotype was not available for that drug, an age
effect on clearance of the 9-hydroxyrisperidone moiety, and sex, race,
and age effects on olanzapine disposition.
2.3. Estimation of dopamine D2 receptor occupancy
By using the estimated plasma concentrations of antipsychotics at
peak and trough at 3 months, corresponding dopamine D2 receptor
occupancy levels were estimated, using the model that we recently
developed (Uchida et al., 2011b). Brieﬂy, dopamine D2 receptor occu-
pancy levels were estimated by incorporating the estimated plasma
concentration of risperidone active moiety, olanzapine, or ziprasidone
into the following one-site binding model: occupancy (%) = a ×
[plasma level / (plasma level + ED50)], where a is the maximum
receptor occupancy attributable to the antipsychotic drug and ED50
is the estimated plasma concentration of the antipsychotic drug
associated with 50% of receptor occupancy, which was obtained
in the systematic review and pooled analysis (risperidone active
moiety: a = 88.0%, ED50 = 4.9 ng/mL; olanzapine: a = 90.7%,
ED50 = 7.1 ng/mL; ziprasidone: a = 88.2%, ED50 = 32.9 ng/mL)
(Uchida et al., 2011b). Mean values of peak and trough dopamine
D2 receptor occupancy levels were obtained for further analyses.
2.4. Statistical analysis
Statistical analyses were carried out by using the SPSS Version
19.0 (SPSS Inc., Chicago). A multivariate general linear model was
used to examine the effects of estimated dopamine D2 receptor occu-
pancy levels, age, sex, race, and smoking status on serum prolactin
Table 2
Sensitivity and speciﬁcity of a series of cutoff points in the estimated dopamineD2 receptor
occupancy for hyperprolactinemia.
Cutoff points, % Sensitivity Speciﬁcity Accuracy
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based on the presence of hyperprolactinemia (i.e. >18.77 ng/mL
and >24.20 ng/mL for men and women, respectively) (Marken et
al., 1992) The mean estimated dopamine D2 receptor occupancy
levels were compared between the hyperprolactinemia and the
non-hyperprolactinemia groups, using the independent t-test. A
p-value of b0.05 was considered statistically signiﬁcant (two-tailed).
To evaluate the performance of this binary classiﬁcation, sensitivity
and speciﬁcity of the consecutive cut-off points in increments of 1%
between 50% and 85% in the estimated dopamine D2 receptor occupan-
cy for hyperprolactinemia were calculated. Accuracy, which is deﬁned
as [True Positive + True Negative] / Total N, was also calculated. Accu-
racy depends on the number of observations, whichmay render it infe-
rior to the careful and balanced consideration of sensitivity and
speciﬁcity (Alberg et al., 2004). To address this potential pitfall, cut-off
points that demonstrated a level of 0.5 or greater in both sensitivity
and speciﬁcity with the highest degree of accuracy were examined.
3. Results
3.1. Subject characteristics
Four hundred and eighty-one subjects who provided blood sam-
ples for the assessments of plasma concentrations of risperidone
plus 9-hydroxyrisperidone, olanzapine, or ziprasidone and serum
prolactin concentration at 3 months were included. Demographic
and clinical characteristics of these subjects were summarized in
Table 1. Mean ± SD daily doses of risperidone, olanzapine, and
ziprasidone at 3 months were 4.0 mg ± 1.4 mg, 19.9 ± 7.4 mg, and
120.4 ±35.8 mg, respectively. Mean ± SD serum prolactin concen-
tration was 21.0 ± 22.0 ng/mL (20.9 ± 22.4 ng/mL for males and
21.5 ±21.0 ng/mL for females).
3.2. Association between estimated D2 receptor occupancy and serum
prolactin concentration
The multivariate general linear model revealed that while age, sex,
race, and smoking status failed to demonstrate any statistically signif-
icant effect on serum prolactin concentration, the estimated dopa-
mine D2 receptor occupancy levels statistically showed a positive
association with the serum prolactin concentration (Corrected
model: F[1, 458] = 43.0, p b 0.001, R2 = 0.12). When the subjects
were divided into the two groups according to the presence of
hyperprolactinemia, the mean ± SD estimated dopamine D2 receptor
occupancy was signiﬁcantly higher in subjects who experienced
hyperprolactinemia (N = 170) than those who did not (N = 311)
(72.4 ± 8.7% vs. 64.1 ± 14.9%, p b 0.001). We then conducted
additional analyses to ﬁnd the threshold. Sensitivity and speciﬁcity of
a series of cut-off points for estimated dopamine D2 occupancy areTable 1
Demographic and clinical characteristics of the patients (N = 481).
Characteristics Values
Age, years, mean ± SD (range) 41.4 ± 10.8 (18–66)
Male, N (%) 349 (72.6%)
Race
Caucasian, N (%) 295 (61.3%)
African-American, N (%) 160 (33.3%)
Native American, N (%) 4 (0.8%)
Asian, N (%) 12 (2.5%)
Native Hawaiian or other Paciﬁc Islander, N (%) 1 (0.2%)
Mixed, N (%) 9 (1.9%)
Smoking, N (%) 324 (67.4%)
Medication
Risperidone, N (%) 172 (35.8%)
Olanzapine, N (%) 211 (43.9%)
Ziprasidone, N (%) 98 (20.4%)presented in Table 2. The cut-off point of 73% resulted in 0.5 or greater
in both sensitivity and speciﬁcity with the highest degree of accuracy.
When they were separately analyzed in the same way, the cut-off
points for hyperprolactinemia were 68–70% for risperidone, 77% for
olanzapine, and 55% for ziprasidone. Plasma concentrations of risperi-
done plus 9-hydroxyrisperidone, olanzapine, and ziprasidone corre-
sponding to those cut-off point were 16.7–19.1 ng/mL, 39.9 ng/mL, and
54.5 ng/mL, respectively, using the one-site binding models described
above.4. Discussion
To our knowledge, this is the largest study to investigate the relation-
ship between serum prolactin concentration and estimated dopamine
D2 receptor blockade with risperidone, olanzapine, or ziprasidone in
patients with schizophrenia. Our results support previous reports of a
signiﬁcant association between dopamine D2 receptor occupancy levels
and serum prolactin concentration. Our data extend these observations
through the demonstration of a threshold of hyperprolactinemia at 73%
of striatal dopamine D2 receptor occupancy;moreover, it seems to differ
among antipsychotic drugs. These differences in the cutoff points might
be derived from the dissociation between central and peripheral dopa-
mine D2 occupancy levels (Kapur et al., 2002).
Previous brain imaging studies have consistently shown the
presence of a therapeutic window of 65–80% occupancy in the striatal
dopamine D2 receptors (Farde et al., 1995; Kapur et al., 2000; Uchida
et al., 2011a); it is associated with optimal therapeutic efﬁcacy during
acute treatment in younger patients while minimizing risks of extra-
pyramidal symptoms (Farde et al., 1992; Kapur et al., 2000) and cog-
nitive impairments (Sakurai et al., 2013). Data from the present study
provide further support of this therapeutic range from the perspec-
tive of antipsychotic-induced hyperprolactinemia. Among previous
studies that investigated the relationship between dopamine D2
receptor occupancy and hyperprolactinemia (Baron et al., 1989;
Kapur et al., 2000; Schlegel et al., 1996), Kapur et al. demonstrated in
their PET study that the likelihood of hyperprolactinemia increased sig-
niﬁcantly as the dopamine D2 occupancy exceeded 72% for haloperidol.
As described in the Introduction, Arakawa et al. also conducted a PET
study and reported that signiﬁcant positive correlation was observed
between the plasma concentration of prolactin and the dopamine D2
receptor occupancy in the anterior pituitary, suggesting that 50%
dopamine D2 occupancy in the pituitary as the threshold level of85 0.01 1.00 0.66
80 0.16 0.91 0.65
75 0.45 0.71 0.62
74 0.52 0.69 0.63
73 0.58 0.68 0.64
72 0.62 0.64 0.63
71 0.69 0.6 0.63
70 0.76 0.58 0.63
69 0.73 0.56 0.62
68 0.75 0.52 0.60
67 0.78 0.48 0.59
66 0.81 0.46 0.58
65 0.84 0.42 0.57
60 0.90 0.32 0.52
55 0.95 0.23 0.49
50 0.98 0.18 0.46
Bold values represent cutoff point associated with >0.5% in both sensitivity and
speciﬁcity.
The italicized value represent the cutoff point associated with >0.5% in both sensitivity
and speciﬁcity with the highest degree of accuracy.
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imaging data have not always shown such an association (Mamo et
al., 2004; Remington et al., 2006) probably, in part, due to small sample
sizes (16 at the largest). Although the dopamine D2 receptor occupan-
cy was not measured but estimated, the present study with the large
sample size of 481 conﬁrmed the signiﬁcant association between
hyperprolactinemia and dopamine D2 receptor occupancy levels in pa-
tients with schizophrenia. Furthermore, the results suggest that the
73% of dopamine D2 receptor occupancy ﬁgure with antipsychotics
could serve as a threshold of hyperprolactinemia in the treatment of
schizophrenia.
Minimizing exposure to antipsychotics is important in light of
their dose dependent side effects such as sudden cardiac death (Ray
et al., 2009), negative subjective well-being (Mizrahi et al., 2007),
and extrapyramidal side effects (Kapur et al., 2000; Uchida et al.,
2011a). The ﬁndings in the present study also corroborate such strat-
egy to counteract hyperprolactinemia and emphasize the relevance of
using low antipsychotic dosage to minimize the risk of this D2
occupancy-dependent side effect in the treatment of schizophrenia.
However, although ameta-analysis indicates that a lower antipsychotic
dosage strategy for relapse prevention in schizophrenia may not com-
promise effectiveness (Uchida et al., 2011c), this treatment approach
should be employed in careful consideration of inter-individual differ-
ences in dose requirements (Uchida et al., 2009b, 2009c).
The results of this study should be interpreted in light of various
limitations. First, only patients treated with risperidone, olanzapine,
or ziprasidone were included in this study since both the population
pharmacokinetic models (Bigos et al., 2008; Feng et al., 2008;
Wessels et al., 2011) and the prediction model of dopamine D2 recep-
tor occupancy from plasma concentrations (Uchida et al., 2011b)
were available only for those three drugs. Although these drugs rep-
resent commonly prescribed atypical antipsychotics, any extrapola-
tion of the ﬁndings to other antipsychotics must be made within
this context. Second, dopamine D2 receptor occupancy was not mea-
sured with brain imaging techniques, but it was calculated with the
model we developed although the predictive performance of the
model has been shown to be reliable (Uchida et al., 2011b). Moreover,
the region of interest in 97% of the PET data used for the development
of this prediction model was the striatum of basal ganglia (Uchida et
al., 2011b). The ﬁndings in the present study need to be replicated in
future investigations, using radiotracers that can directly be assess-
able to extrastriatal dopamine receptors, especially those in the ante-
rior pituitary, which is located outside the blood–brain barrier (Kapur
et al., 2002). Third, the incidence of hyperprolactinemia differs among
antipsychotics. It has been reported that risperidone presented a high
risk of hyperprolactinemia, while olanzapine and ziprasidone showed
a relatively low risk (Volavka et al., 2004; Melkersson, 2005; Komossa
et al., 2009). In contrast, in the present study, the cut-off point for
hyperprolactinemia in patients receiving ziprasidone was lower
than the other two drugs. One possible reason of this unexpected
ﬁnding may be a relatively short peripheral and central half-life of
this drug. Our group recently demonstrated in a PET study that the
time-course of receptor occupancy across the regions indicated a D2
occupancy half-life of 8.3 h (Suzuki et al., in press), suggesting rapid
ﬂuctuation in prolactin level as well. Moreover, there were only 17
subjects (17.3%) who presented hyperprolactinemia in the ziprasidone
groupwith only 2 of them showing estimated D2 occupancy levels over
70%. These issuesmaymake it difﬁcult toﬁnd a robust threshold for this
particular agent. Forth, there are previous studies that found increased
prolactin concentrations in antipsychotic-naïve patients with schizo-
phrenia (Aston et al., 2010; Lee and Kim, 2006), which indicates that
hyperprolactinemia thatwe observed in this studymay not be solely at-
tributable to blockade of dopamine D2 receptors with antipsychotic
drugs. Finally, we did not take into account normal ﬂuctuations of
serumprolactin concentrations; it iswidely known that serumprolactin
concentrations rise during sleep and decrease during the day (VanCauter et al., 1981). Furthermore, menstrual cycle phases also affect its
concentration in premenopausal women (Musey et al., 1987).
In conclusion, the threshold for hyperprolactinemia in dopamine D2
receptor occupancy was found to be 73%, which lies somewhat on a
lower side of the established therapeutic window with antipsychotics
(65–80%). Given that this often invisible side effect could cause a
variety of serious consequences in the both short and long runs,
minimizing exposure to antipsychotics while keeping their clinical
effectiveness is critically important in the treatment of schizophrenia.
Although the ﬁndings in the present study need to be replicated in pro-
spective brain imaging studies that focus on the pituitary in particular,
they endorse the clinical relevance of using the lowest possible dose of
antipsychotics.
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